Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Shares Outstanding (Weighted Average): 2022-2025

Historic Shares Outstanding (Weighted Average) for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $102.4 million.

  • Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) rose 16.72% to $102.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.4 million, marking a year-over-year increase of 16.72%. This contributed to the annual value of $100.8 million for FY2024, which is 15.86% up from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) stood at $102.4 million, which was up 1.06% from $101.4 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $102.4 million during Q3 2025, and its lowest value of $61.9 million during Q2 2022.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $90.0 million, with a median of $87.4 million in 2024.
  • Data for Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY climbed of 18.83% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Day One Biopharmaceuticals' Shares Outstanding (Weighted Average) stood at $73.5 million in 2022, then rose by 18.35% to $87.0 million in 2023, then climbed by 15.86% to $100.8 million in 2024, then climbed by 16.72% to $102.4 million in 2025.
  • Its last three reported values are $102.4 million in Q3 2025, $101.4 million for Q2 2025, and $101.4 million during Q1 2025.